The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases — an international Delphi consensus survey
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 775 KB, PDF-dokument
Background: Intestinal ultrasound (IUS) is a non-invasive modality for monitoring disease activity in inflammatory bowel diseases (IBD). IUS training currently lacks well-defined standards and international consensus on competency criteria. Aim: To achieve international consensus on what competencies should be expected from a newly certified IUS practitioner. Methods: A three-round, iterative Delphi process was conducted among 54 IUS experts from 17 countries. Round 1 was a brainstorming phase with an open-ended question to identify the knowledge and skills that experts believe a newly certified IUS practitioner should possess. The experts' suggestions were then organised into statements by a Steering Committee. In round 2, the experts commented upon and rated the statements, which were revised accordingly. In round 3, the experts rated the revised statements. Statements meeting the pre-defined consensus criterion of at least 70% agreement were included in the final list of statements. Results: In total, 858 items were suggested by the experts in the first round. Based on these suggestions, 55 statements were organised into three categories: knowledge, technical skills and interpretation skills. After the second round, 53 revised statements remained. After the final round, a total of 41 statements had achieved consensus. Conclusions: We established international, expert consensus on the knowledge and skills that should be expected from newly certified IUS practitioners. These consensus statements are the first step towards mastery learning for IUS training. Educators can utilise these statements to design training programmes and evaluate the competencies of trainees before they engage in independent practice.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Alimentary Pharmacology and Therapeutics |
| Vol/bind | 56 |
| Udgave nummer | 2 |
| Sider (fra-til) | 263-270 |
| Antal sider | 8 |
| ISSN | 0953-0673 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
Gorm Roager Madsen and Trine Boysen: None to declare. Rune Wilkens: Personal fees from AbbVie, Janssen, Pfizer, Takeda, Alimentiv outside the submitted work. Johan Burisch: Personal fees from AbbVie, grants and personal fees from Janssen‐Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos. None of these pertain to the work submitted here. Robert Bryant: reports Grant/Research support/Speaker fees (all paid to employer for research support): AbbVie, Ferring, Janssen, Shire, Takeda, Emerge Health (outside of submitted work); shareholder in Biomebank. Dan Carter: Consulting fees from Takeda, Abbvie, Taro and Lapidot, Speaker fees and/or research support from Takeda, Abbvie, Janssen and Lapidot. Krisztina Gecse: has received grants from Pfizer Inc, Galapagos and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts. Christian Maaser: consulting and/or speaking fees from: Abbvie, Biogen, Dr. Falk PharmaGmbH, Ferring Arzneimittel GmbH, Galapagos, Gilead, Janssen, MSD Sharp & Dome GmbH, Pfizer, Roche, Samsung, Takeda PharmaGmbH, Vifor Pharma. Giovanni Maconi: reports personal fees from Alfa‐Sigma, Arena Pharmaceuticals, Fresenius‐Kabi, Gilead, Janssen‐Cilag, Roche, outside the submitted work. Kerri Novak: reports advisory board fees from AbbVie, Janssen, Pfizer, Takeda; speaker's fees from AbbVie, Janssen, Takeda, Pfizer; and research support from AbbVie and Takeda. Carolina Palmela: Personal fees from Janssen and Laboratorios Vitoria, outside the submitted work. Leizl Joy Nayahangan, Martin Grønnebæk Tolsgaard: None to declare. Declaration of personal interests:
Funding Information:
We would like to acknowledge the Delphi panellists for participating in the process. The Delphi panellists are listed in Table S2. Declaration of personal interests: Gorm Roager Madsen and Trine Boysen: None to declare. Rune Wilkens: Personal fees from AbbVie, Janssen, Pfizer, Takeda, Alimentiv outside the submitted work. Johan Burisch: Personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos. None of these pertain to the work submitted here. Robert Bryant: reports Grant/Research support/Speaker fees (all paid to employer for research support): AbbVie, Ferring, Janssen, Shire, Takeda, Emerge Health (outside of submitted work); shareholder in Biomebank. Dan Carter: Consulting fees from Takeda, Abbvie, Taro and Lapidot, Speaker fees and/or research support from Takeda, Abbvie, Janssen and Lapidot. Krisztina Gecse: has received grants from Pfizer Inc, Galapagos and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts. Christian Maaser: consulting and/or speaking fees from: Abbvie, Biogen, Dr. Falk PharmaGmbH, Ferring Arzneimittel GmbH, Galapagos, Gilead, Janssen, MSD Sharp & Dome GmbH, Pfizer, Roche, Samsung, Takeda PharmaGmbH, Vifor Pharma. Giovanni Maconi: reports personal fees from Alfa-Sigma, Arena Pharmaceuticals, Fresenius-Kabi, Gilead, Janssen-Cilag, Roche, outside the submitted work. Kerri Novak: reports advisory board fees from AbbVie, Janssen, Pfizer, Takeda; speaker's fees from AbbVie, Janssen, Takeda, Pfizer; and research support from AbbVie and Takeda. Carolina Palmela: Personal fees from Janssen and Laboratorios Vitoria, outside the submitted work. Leizl Joy Nayahangan, Martin Grønnebæk Tolsgaard: None to declare.
Publisher Copyright:
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
ID: 313472650